AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (previously presented) An intraluminal device, suitable for implantation in a body, which device is provided with a coating, wherein the coating comprises:

50-97% heparan sulfate;

1-20% laminin; and

0.2-15% type IV collagen.

2. (previously presented) The intraluminal device according to claim 1, wherein the coating comprises:

75-95% heparan sulfate;

3-10% laminin; and

0.5-10% type IV collagen.

3. (canceled)

4. (previously presented) The intraluminal device according to claim 1, wherein the coating further comprises a growth factor.

5. (previously presented) The intraluminal device according to claim 4, wherein the growth factor is selected from the group consisting of bFGF, IGF, TGF-β and VEGF.

6. (previously presented) An intraluminal device, suitable for implantation in a body, the device being provided with a coating that comprises:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen; and

an antibiotic.

7. (currently amended) ~~The intraluminal device according to claim 6, wherein the antibiotic comprises~~ An intraluminal device, suitable for implantation in a body, the device being provided with a coating that comprises:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen; and

an antibiotic comprising gentamycine.

8. (previously presented) The intraluminal device according to claim 1, wherein the coating further comprises vitronectine.

9. (previously presented) The intraluminal device according to claim 1, wherein the coating comprises:

85-95% heparan sulfate;

5-6% laminin;

3-4% type IV collagen;

0.5-1.5% entactin and nidogen;

0.001-1% growth factors; and

0.001-1% antibiotic.

10. (previously presented) The intraluminal device according to claim 1, wherein the intraluminal device is a prosthesis that comprises a stent or a graft.

11. (previously presented) A coating suitable for the intraluminal device according to claim 1.

12. (previously presented) A method for preparing an intraluminal device, comprising the steps of:

- providing an intraluminal device for implantation in a body;

- preparing a composition, comprising, in about 50 mg/ml solvent:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen; and

the solvent being a suitable buffer or water;

- dipping the intraluminal device in the composition; and

- drying the dipped intraluminal device.

13. (previously presented) The method according to claim 12, wherein the composition further comprises entactin and nidogen.

14. (previously presented) The method according to claim 12, wherein the composition further comprises a growth factor, selected from the group consisting of bFGF, IGF, TGF-β and VEGF.

15. (previously presented) The method according to claim 12, wherein the composition further comprises an antibiotic.

16. (previously presented) The method according to claim 12, wherein the composition further comprises vitronectin.

17. (previously presented) The method according to claim 12, wherein the composition comprises:

85-95% heparan sulfate;

5-6% laminin;

3-4% type IV collagen;

0.5-1.5% entactin and nidogen;

0.001-1% growth factors; and

0.001-1% antibiotic.

18. (previously presented) The intraluminal device according to claim 1, wherein the coating further comprises entactin and nidogen.